Related Experiment Videos
Gentamicin in the treatment of staphylococcal infections
Abstract:
The aminoglycoside antibiotic, gentamicin, was used to treat staphylococcal infections in eighty-six patients in an open multicentre trial. Most of the infections involved the skin and soft tissue and the lower respiratory tract. Staphylococcus aureus was the only organism isolated in seventy-four patients; mixed flora were found in twelve. Gentamicin was administered, intramuscularly or intravenously, for 7 to 12 days (mean, 10 days) in a mean dose of 3-27 mg/kg per day. Clinical and bacteriological assessment of results indicated a complete resolution of the infection in fifty-three patients (61-6%) and a marked, moderate, or slight improvement in an additional twenty-nine patients (33.7%). Thus, a total of eighty-two patients ((95.3%) showed cure or improvement while only four patients (4-6%) failed to do so. Staphylococci persisted in six patients. Superinfection also occurred in six patients, however, it was considered to be clinically significant in only four of them. Screening for eighth cranial nerve, renal, hepatic and haematological function, before, during, and after gentamicin treatment, revealed no adverse reactions in these patients.
Insights
Gentamicin effectively treated staphylococcal infections in a multicenter trial. This aminoglycoside antibiotic demonstrated a high cure and improvement rate with no significant adverse reactions observed in patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Staphylococcal infections pose a significant clinical challenge.
- Aminoglycoside antibiotics, such as gentamicin, are utilized for treating bacterial infections.
Purpose of the Study:
- To evaluate the efficacy and safety of gentamicin in treating staphylococcal infections.
- To assess clinical and bacteriological outcomes in patients receiving gentamicin.
Main Methods:
- An open, multicenter trial involving eighty-six patients with staphylococcal infections.
- Gentamicin administered intramuscularly or intravenously for 7-12 days at a mean dose of 3.27 mg/kg/day.
- Monitoring of clinical and bacteriological response, along with eighth cranial nerve, renal, hepatic, and hematological function.
Main Results:
- A total of 95.3% of patients showed cure or improvement.
- Complete resolution was observed in 61.6% of patients.
- No adverse reactions were detected in eighth cranial nerve, renal, hepatic, or hematological function screenings.
Conclusions:
- Gentamicin is an effective and safe treatment for staphylococcal infections.
- The antibiotic demonstrated a high success rate with a favorable safety profile.
- Further research may explore gentamicin's role in specific staphylococcal infection types.